137 related articles for article (PubMed ID: 14577318)
41. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
[TBL] [Abstract][Full Text] [Related]
42. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
43. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
Kiguchi T; Tauchi T; Ohyashiki K
Rinsho Ketsueki; 2009 Jan; 50(1):52-4. PubMed ID: 19225231
[TBL] [Abstract][Full Text] [Related]
44. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
45. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Sneed TB; Kantarjian HM; Talpaz M; O'Brien S; Rios MB; Bekele BN; Zhou X; Resta D; Wierda W; Faderl S; Giles F; Cortes JE
Cancer; 2004 Jan; 100(1):116-21. PubMed ID: 14692031
[TBL] [Abstract][Full Text] [Related]
46. [Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
Morita R; Hashino S; Sogabe S; Dazai M; Onozawa M; Izumiyama K; Kondo T; Ota S; Kobayashi S; Imamura M; Asaka M
Rinsho Ketsueki; 2004 Oct; 45(10):1105-10. PubMed ID: 15553045
[TBL] [Abstract][Full Text] [Related]
47. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Wodarz D
Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
[TBL] [Abstract][Full Text] [Related]
48. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
49. [Imatinib therapy for patients with chronic myelogenous leukemia].
Usui N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
[TBL] [Abstract][Full Text] [Related]
50. Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
Ramamoorthy SK; Pandita R; Prakash A; Ramaswamy NV; Al Bahar S
Acta Haematol; 2007; 118(3):141-5. PubMed ID: 17804901
[TBL] [Abstract][Full Text] [Related]
51. Relationship of serum imatinib trough level and response in CML patients: long term follow-up.
Awidi A; Ayed AO; Bsoul N; Magablah A; Mefleh R; Dweiri M; Ramahi M; Arafat E; Bishtawi M; Marie L
Leuk Res; 2010 Dec; 34(12):1573-5. PubMed ID: 20688395
[TBL] [Abstract][Full Text] [Related]
52. Autologous peripheral blood stem cell transplantation of stem cells harvested in imatinib-induced complete cytogenetic remission: an example of in vivo purging in CML.
le Coutre P; Kreuzer KA; Massenkeil G; Baskaynak G; Zschieschang P; Genvresse I; Lupberger J; Mapara M; Dörken B; Arnold R
Leukemia; 2003 Dec; 17(12):2525-6. PubMed ID: 14562118
[No Abstract] [Full Text] [Related]
53. Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate.
Simpson E; O'Brien SG; Reilly JT
Clin Lab Haematol; 2006 Jun; 28(3):215-6. PubMed ID: 16706941
[No Abstract] [Full Text] [Related]
54. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
[TBL] [Abstract][Full Text] [Related]
55. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
Fujisawa S; Yano K; Kobayashi M
Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
[TBL] [Abstract][Full Text] [Related]
56. [Successful attainment of the third chronic phase by autologous peripheral blood stem cell transplantation and imatinib in a patient with chronic myeloid leukemia].
Tabata S; Ohno T; Tomo K; Hishita T; Hada S; Mizumoto T; Furukawa H
Rinsho Ketsueki; 2003 May; 44(5):313-7. PubMed ID: 12822405
[TBL] [Abstract][Full Text] [Related]
57. What is the dose of STI-571 needed to induce a molecular remission in chronic myeloid leukemia?
Ruiz-Argüelles GJ
Haematologica; 2002 Mar; 87(3):ELT15. PubMed ID: 11869961
[No Abstract] [Full Text] [Related]
58. Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.
Breccia M; Stagno F; Vigneri P; Latagliata R; Cannella L; Del Fabro V; Di Raimondo F; Alimena G
Am J Hematol; 2010 May; 85(5):375-7. PubMed ID: 20306543
[No Abstract] [Full Text] [Related]
59. Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
Yujiri T; Sato Y; Tanizawa Y
Int J Hematol; 2004 Jul; 80(1):67-9. PubMed ID: 15293571
[TBL] [Abstract][Full Text] [Related]
60. Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
Stagno F; Stella S; Berretta S; Massimino M; Antolino A; Giustolisi R; Messina A; Di Raimondo F; Vigneri P
Leuk Res; 2008 Apr; 32(4):673-4. PubMed ID: 17889935
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
